Patent Application
20200129596
Glioblastoma is the most deadly primary brain tumor. Even with the combined surgical resection, radiation therapy, and chemotherapy, median survival of patients is less than 15 months after diagnosis (Stupp et al., 2009; Johnson and O'Neill, 2012). Lack of success in treating glioblastoma likely arises from tumor heterogeneity and the treatment resistance of glioblastoma stem cells (GSCs), a population of cancer stem cells with extraordinary capacity to promote tumor growth, invasion, and display increased resistance to radiotherapy and chemotherapy (Singh et al., 2004; Bao et al., 2006; Godlewski et al., 2010). The presence of these cancer stem cells renders glioblastoma treatment-resistant and recurring (Sundar et al., 2014). Therefore new cancer therapies, including glioblastoma therapies, that target these treatment-resistant cancer stem cells are urgently needed (Godlewski et al., 2010; Allegra et al., 2014).
In one aspect, the disclosure provided herein relates to a method of treating cancer in a subject by promoting m6A modification and/or decreasing m6A demethylation. The method entails administering a therapeutic effective amount of one or more therapeutic agents to the subject to increase the expression of methyltransferase-like 3 (METTL3) or methyltransferase-like 14 (METTL14), or to inhibit the expression of fat mass and obesity-associated protein (FTO) gene, alkylation repair homologue protein 5 (ALKBH5) gene, or nuclear receptor TLX gene. Alternatively, the method entails knocking out the FTO gene, the ALKBH5 gene, or the TLX gene, e.g., by CRISPR-Cas9 or other known methods in the art. In some embodiments, the cancer is an m6A related cancer, such as glioblastoma, leukemia (e.g., acute myeloid leukemia), stomach cancer, prostate cancer, colorectal cancer, endometrial cancer, breast cancer, pancreatic cancer, kidney cancer, mesothelioma, sarcoma, etc.
In another aspect, the disclosure provided herein relates to a pharmaceutical composition comprising a therapeutically effective amount of one or more therapeutic agents that increase the expression or activity of METTL3 or METTL14, or that inhibit the expression or activity of FTO, ALKBH5, or TLX. The pharmaceutical composition may comprise one or more additional ingredients, such as a pharmaceutically acceptable excipient, carrier, diluent, surfactant, diluent, preservative, etc. The pharmaceutical composition can be formulated into any dosage form suitable for a particular administration route, such as parenteral injection, oral administration, intracranial injection, etc. The pharmaceutical composition can be in liquid, semi-solid (e.g., gel), or solid formulation. In some embodiments, the pharmaceutical composition includes a small molecule that inhibits FTO, ALKBH5, or TLX, or an anti-FTO, anti-ALKBH5, or anti-TLX antibody. In some embodiments, the small molecule FTO inhibitor is a meclofenamic acid (MA) or a derivative thereof, such as MA2. Additionally, the pharmaceutical composition can also include small RNAs such as miRNA, siRNAs or shRNAs for inhibiting FTO, ALKBH5, or TLX.
The following description of the invention is merely intended to illustrate various embodiments of the invention. As such, the specific modifications discussed are not to be construed as limitations on the scope of the invention. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the scope of the invention, and it is understood that such equivalent embodiments are to be included herein.
More than 100 RNA modifications have been reported, including modifications within mRNAs (Machnicka et al., 2013), among which, N6-methyladenosine (m6A) modification is the most prevalent internal modification in eukaryotic mRNAs (Wei et al., 1975). Although discovered in the 1970s (Desrosiers et al., 1974; Wei and Moss, 1974; Dubin and Taylor, 1975; Perry et al., 1975), the physiological significance of m6A modification in mRNA has only been appreciated until recent years because of breakthrough findings of two mammalian RNA demethylases, the fat mass and obesity-associated protein (FTO) and alkylation repair homologue protein 5 (ALKBH5), which demonstrated that m6A methylation is a dynamic and reversible modification (Jia et al., 2011; Zheng et al., 2013). Transcriptome-wide m6A profiling further showed that m6A modification is presented in thousands of RNA transcripts with unique distribution patterns (Dominissini et al., 2012; Meyer et al., 2012).
The formation of m6A modification is catalyzed by a methyltransferase complex that contains methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), and Wilm's tumor 1-associating protein (WTAP) in mammalian cells (Bokar et al., 1994; Liu et al., 2014; Ping et al., 2014; Wang et al., 2014). Knockdown (KD) of either METTL3 or METTL14 induces a substantial decrease in m6A level in mRNA (Liu et al., 2014; Wang et al., 2014). While m6A methyltransferases and demethylases act as its writers and erasers, respectively, m6A readers selectively bind to m6A-containing RNA to mediate downstream effects (Yue et al., 2015).
The roles of RNA modifications in biological processes have just begun to be appreciated. RNA modifications have been implicated in embryonic stem cell maintenance and differentiation (Batista et al., 2014; Wang et al., 2014; Geula et al., 2015), circadian rhythm modification (Fustin et al., 2013), heat shock response (Zhou et al., 2015), meiotic progression (Schwartz et al., 2013), and neuronal function (Lemkine et al., 2005). However, the function of the majority of RNA modifications found in mRNAs remains unknown. Specifically, the functional roles of m6A methylation in cancer initiation and progression remain to be determined. The identification of the writers, readers and erasers of m6A modification and the development of the m6A-seq technology set the foundation for the field to define the roles of m6A mRNA modification in cancer biology.
As demonstrated in the working examples, knockdown of METTL3 or METTL14 expression dramatically increased GSC growth and self-renewal. In contrast, overexpression of METTL3 and/or METTL14, or treatment with MA2, a chemical inhibitor of the RNA demethylase FTO, inhibited GSC growth and self-renewal considerably. By transplanting METTL3 shRNA or METTL14 shRNA-transduced GSCs into immunodeficient NOD SCID Gamma (NSG) mice, it was shown that knockdown of METTL3 or METTL14 expression led to substantial increase of GSC-initiated tumor progression in transplanted mouse brains. Furthermore, treatment with MA2, a chemical inhibitor of FTO, dramatically suppressed GSC-induced tumorigenesis and prolonged the lifespan in GSC-grafted animals.
As demonstrated in this disclosure, controlling mRNA m6A level is critical for maintaining GSC growth, self-renewal, and tumor development. Knockdown of METTL3 or METTL14 expression reduced mRNA m6A level, enhanced the growth and self-renewal of GSCs in vitro, and promoted the ability of GSCs to form brain tumors in vivo. In contrast, overexpression of METTL3 or treatment with the FTO inhibitor MA2, increased mRNA m6A level in GSCs and suppressed GSC growth. Moreover, treatment of GSCs with the FTO inhibitor MA2 suppressed GSC-initiated tumorigenesis and prolonged the lifespan of GSC-engrafted mice. The finding that the FTO inhibitor MA2 suppresses GSC-initiated brain tumor development suggests that m6A methylation could be a promising target for cancer therapy, e.g., anti-glioblastoma therapy.
This disclosure relates to mRNA m6A modification in regulating GSC self-renewal and tumorigenesis. Study of mRNA modification is a nascent field as yet, and the significance of this epigenetic mark in controlling cell growth and differentiation is just beginning to be appreciated. Although m6A is most abundant in the brain (Meyer et al., 2012), no study on the role of m6A modification in either brain development or brain disorders has been reported yet, except recent studies demonstrating a role of m6A in Drosophila neuronal function (Haussmann et al., 2016; Lence et al., 2016). Moreover, the role of m6A in cancer is only starting to be revealed (Zhang et al., 2016; Li et al., 2017). In some embodiments, disclosed herein is a correlation between mRNA m6A methylation and glioblastoma tumorigenesis, which represents an important step towards developing novel therapeutic strategies to treat cancer, such as glioblastoma by targeting m6A modification, its upstream regulators or downstream targets in GSCs.
RNA epigenetics has become a fast-moving research field in biology and holds great promise for future therapeutic development for human diseases. The m6A modification, installed by a methyltransferase complex consisting of METTL3 and METTL14, is one of the most common and abundant modifications on mRNAs in eukaryotes. The evidence is clear that m6A methylation is more than a mere “decoration” of the mRNA. The reversible nature of m6A methylation strongly suggests a regulatory role for this RNA modification (Sibbritt et al., 2013). Such a role could be important during dynamic cell growth and differentiation process. Indeed, a role for m6A modification in controlling embryonic stem cell pluripotency and differentiation has been reported (Batista et al., 2014; Wang et al., 2014; Chen et al., 2015; Geula et al., 2015). Although components of the m6A methylation machinery have been linked to cancer (Linnebacher et al., 2010; Kaklamani et al., 2011; Pierce et al., 2011; Machiela et al., 2012; Long et al., 2013; Lin et al., 2016; Zhang et al., 2016), whether the effect is dependent on m6A modification remains to be clarified. A recent study demonstrated that METTL3 enhances translation in cancer cells independently of m6A modification (Lin et al., 2016). On the other hand, elevated levels of S-adenosyl methionine (SAM) donor of the methyl group in m6A methylation process has been shown to suppress cell growth in cancer (Pascale et al., 2002; Pakneshan et al., 2004; Guruswamy et al., 2008; Lu et al., 2009; Zhao et al., 2010). However, whether the growth-inhibitory effect of increased levels of SAM is caused by elevated levels of m6A modification remains unknown. A direct causative link between mRNA m6A methylation and tumorigenesis remains to be established (Sibbritt et al., 2013). Disclosed herein is the biological significance of m6A modification in glioblastoma biology by defining the role of m6A modification in GSC self-renewal and tumorigenesis via targeting multiple components of the m6A regulatory machinery, including METTL3, METTL14 and FTO.
This disclosure identified roles of m6A modification in glioblastoma, the most aggressive and invariably lethal brain tumor. GSCs which are implicated in the initiation and development of glioblastoma were studied. The results demonstrate that modulation of mRNA m6A level impacts multiple aspects of GSCs, including GSC growth, self-renewal, and tumorigenesis, suggesting that mRNA m6A modification may serve as promising targets for GSCs. Furthermore, m6A-seq analysis was performed in GSCs with knockdown of METTL3 or METTL14. This transcriptome-wide analysis revealed genes and pathways that are impacted by mRNA m6A modification in GSCs, which could also serve as potential molecular targets to inhibit GSC tumorigenesis for the treatment of glioblastoma. Additionally, as demonstrated herein, nuclear receptor TLX is essential for GSC self-renewal and tumorigenicity and can be an upstream regulator of m6A RNA modification in GSCs. M6A RNA modification is increased by TLX knockout or knockdown. Moreover, the TLX knockdown-induced growth inhibition in GSCs is reversed by knockdown of METTL3.
In one aspect, disclosed herein is a method for treating a subject suffering from a cancer. The method includes increasing mRNA m6A methylation level in the cancer stem cells. In some embodiments, the mRNA m6A methylation level is increased by overexpressing METTL3, overexpressing METTL14, inhibiting FTO, ALKBH5 or TLX, or a combination thereof. For example, the promoters of METTL3 or METTL14 can be activated and/or CRISPRa can be used to promote overexpression of METTL3 or METTL14. Moreover, administration of METTL3 mRNA, protein or a functional fragment thereof and/or administration of METTL14 mRNA, protein or a functional fragment thereof, and/or administration of small molecules that activates the activity of METT3 or METTL14 can also be used as a therapy. In some embodiments, the method entails administering one or more doses of a therapeutically effective amount of an FTO inhibitor, an ALKBH5 inhibitor, and/or a TLX inhibitor to the subject. FTO inhibitors are known in the art, such as small molecule FTO inhibitors and FTO antibodies or fragments thereof. Various small molecule FTO inhibitors have been developed and known in the art, including but not limited to MA, MA2 or other MA derivatives, 4-chloro-6-(6′-chloro-7′-hydroxy-2′,4′,4′-trimethyl-chroman-2′-yl)benzene-1,3-diol (CHTB), etc. FTO antibodies or immunogenic fragments of the antibodies, can be used for treating m6A methylation-related cancer. It is known in the art that polyclonal antibodies, monoclonal antibodies, human antibodies, and humanized antibodies can be used in therapy. Moreover, antibody fragments, including but not limited to, Fab fragments, Fab′ fragments, Fc fragments, and scFV fragments, can also be used as therapeutic agents. Alternatively, FTO gene can be knocked out by a known technique, for example, gene mutation, gene deletion, recombination, small RNAs (miRNA, siRNAs, shRNAs) or CRISPR/Cas9. Likewise, ALKBH5 small molecule inhibitors, antibodies, or small RNAs (miRNAs, siRNAs, shRNAs) or known gene knockout methods such as CRISPA/Cas9, can also be used in therapy. Furthermore, small RNAs (miRNAs, siRNAs, shRNAs) that inhibit TLX or known gene knockout methods such as CRISPA/Cas9 can be used to knock out or knock down TLX.
The term “subject” or “patient” as used herein refers to a subject who is suffering from a cancer condition, e.g., an m6A related cancer, such as glioblastoma, leukemia (e.g., acute myeloid leukemia), stomach cancer, prostate cancer, colorectal cancer, endometrial cancer, breast cancer, pancreatic cancer, kidney cancer, mesothelioma, sarcoma, etc. The subject or patient can be an animal, a mammal, or a human.
The terms “treat,” “treating,” and “treatment” as used herein with regard to a cancer condition refer to alleviating the condition partially or entirely, or eliminating, reducing, or slowing the development of one or more symptoms associated with the condition. In some embodiments, the term “treat,” “treating,” or “treatment” means that one or more symptoms of the cancer condition or complications are alleviated in a subject receiving the treatment as disclosed herein comparing to a subject who does not receive such treatment.
The phrase “an effective amount” or “a therapeutically effective amount” as used herein refers to an amount of a therapeutic agent that produces a desired therapeutic effect. For example, an effective amount of an FTO inhibitor may refer to that amount that treats cancer, e.g., glioblastoma. The precise effective amount is an amount of the therapeutic agent that will yield the most effective results in terms of efficacy in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic agent (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration. One skilled in the clinical and pharmacological arts will be able to determine a therapeutically effective amount through routine experimentation, namely by monitoring a subject's response to administration of a compound and adjusting the dosage accordingly. For additional guidance, see Remington: The Science and Practice of Pharmacy (Gennaro ed. 20th edition, Williams & Wilkins P A, USA) (2000).
According to some embodiments, the therapeutic agents administered to a subject that induce overexpression of METTL3 or METTL14 or that inhibit FTO may be part of a pharmaceutical composition. Such a pharmaceutical composition may include one or more of an agent that induces overexpression of METTL3, an agent that induces overexpression of METTL14, and an agent that inhibits FTO, ALKBH5, and/or TLX, and optionally a pharmaceutically acceptable carrier.
A “pharmaceutically acceptable carrier” as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting an agent or cell of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body. Such a carrier may comprise, for example, a liquid, solid, or semi-solid filler, solvent, surfactant, diluent, excipient, adjuvant, binder, buffer, dissolution aid, solvent, encapsulating material, sequestering agent, dispersing agent, preservative, lubricant, disintegrant, thickener, emulsifier, antimicrobial agent, antioxidant, stabilizing agent, coloring agent, or some combination thereof. Each component of the carrier is “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the composition and must be suitable for contact with any tissue, organ, or portion of the body that it may encounter, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) natural polymers such as gelatin, collagen, fibrin, fibrinogen, laminin, decorin, hyaluronan, alginate and chitosan; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as trimethylene carbonate, ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid (or alginate); (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) alcohol, such as ethyl alcohol and propane alcohol; (20) phosphate buffer solutions; (21) thermoplastics, such as polylactic acid, polyglycolic acid, (22) polyesters, such as polycaprolactone; (23) self-assembling peptides; and (24) other non-toxic compatible substances employed in pharmaceutical formulations such as acetone.
The pharmaceutical compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
In one embodiment, the pharmaceutically acceptable carrier is an aqueous carrier, e.g. buffered saline and the like. In certain embodiments, the pharmaceutically acceptable carrier is a polar solvent, e.g. acetone and alcohol.
In some embodiments, one or more therapeutic agents disclosed above are administered to the subject simultaneously. In some embodiments, one or more therapeutic agents disclosed above are administered to the subject sequentially. The term “simultaneously” as used herein with regards to administration means that one therapeutic agent is administered to the subject at the same time or nearly at the same time of administering another therapeutic agent. For example, two or more therapeutic agents are considered to be administered “simultaneously” if they are administered via a single combined administration, two or more administrations occurring at the same time, or two or more administrations occurring in succession without extended intervals in between.
When multiple doses and/or one or more therapeutic agents are administered, it is within the purview of one of ordinary skill in the art to adjust the administration schedule to optimize the therapeutic effect. In some embodiments, one or more doses and/or one or more therapeutic agents can be administered subsequently after the administration of the first dose or the first therapeutic agent, e.g., within one month of administration of the first dose or first therapeutic agent. For example, the subsequent doses of the therapeutic agent can be administered in one-week intervals or in two-week intervals for an extended period of time, e.g., up to one year. In some embodiments, one or more doses and/or one or more therapeutic agents are administered on a daily basis, every other day, every other two days, or on a weekly basis.
The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.
Cell culture: GSCs derived from patients that were newly diagnosed as grade IV glioblastoma were maintained in sphere cultures as previously described (Cui et al., 2016). Briefly, GSCs were cultured in DMEM-F12 medium (Omega Scientific) supplemented with 1×B27 (Invitrogen), 2 mM L-glutamine (Media Tech), 27.4 mM HEPES (Fisher) and growth factors including 20 ng ml−1 EGF (PeproTech), 20 ng ml−1 FGF (PeproTech) and 5 μg ml−1 heparin (Sigma). All cultures were confirmed for no contamination of mycoplasma using MycoAlert PLUS Mycoplasma Detection Kit (Lonza).
Plasmid DNA: shRNAs were cloned into lentiviral pHIV7-GFP vector. The sequences for shRNAs include control shRNA (5′-ACT CAA AAG GAA GTG ACA AGA-3′) (SEQ ID NO: 1), METTL3 shRNA-1 (5′-GCT GCA CTT CAG ACG AAT T-3′) (SEQ ID NO: 2) (Zhao et al., 2014), METTL3 shRNA-2 (5′-CCA CCT CAG TGG ATC TGT T-3′) (SEQ ID NO: 3) (Dominissini et al., 2012), METTL14 shRNA-1 (5′-GCT AAA GGA TGA GTT AAT-3′) (SEQ ID NO: 4), METTL14 shRNA-2 (5′-GGA CTT GGG ATG ATA TTA T-3′) (SEQ ID NO: 5) (Ping et al., 2014), ADAM19 shRNA-1 (5′-GGA AGA TTT AAA CTC CAT GAA G-3′) (SEQ ID NO: 6), ADAM19 shRNA-2 (5′-CAA AGT GTT CAA TGG ATG CAA C-3′) (SEQ ID NO: 7). The METTL3-expressing lentiviral vector was prepared by subcloning the human METTL3 coding sequences from pcDNA3/Flag-METTL3(Liu et al., 2014) (Addgene plasmid #53739) into the CSC lentiviral vector (Shi et al., 2004). The METTL3 catalytic mutant (aa395-398, DPPW/APPA)-expressing lentiviral vector was prepared by subcloning the mutant human METTL3 sequences from pFLAG-CMV2-METTL3 (mutant) vector (Lin et al., 2016) into the CSC lentiviral vector.
Viral preparation and transduction: Lentiviruses were prepared using 293T cells as described (Shi et al., 2004). To transduce GSCs, cells were dissociated for overnight culture and then incubated with lentivirus and 4 μg ml−1 polybrene (AmericanBio) for 24 h.
Immunostaining: GSC immunostaining was performed as previous described (Cui et al., 2016) using antibodies including mouse anti-GFAP (1:1,000; Sigma; Catalogue # G3893) and rabbit anti-Tuj1 (1:6,000; Covance; Catalogue # PRB-435P).
m6A dot blot assay: GSCs were either maintained in sphere cultures or induced into differentiation for 1 week using 0.5% fetal bovine serum (Sigma) together with 1 μM all-trans retinoic acid (Sigma). Total RNAs were isolated from these GSCs using Trizol reagent (Ambion). GSCs were transduced with lentivirus expressing METTL3 or METTL14 shRNA or METTL3 cDNA. Seven days after transduction, total RNAs were extracted. mRNAs were prepared from total RNAs using Dynabeads® mRNA purification kit (Ambion, Catalog # 61006). Indicated amount of mRNAs was used for dot blot analysis using an antibody specific for m6A (1:1,000; Synaptic Systems; Catalog # 202003). The intensity of dot blot signal was quantified by Image J.
RT-PCR: Total RNAs isolated using Trizol reagent (Ambion) were subjected to reverse transcription (RT) performed using the Tetro cDNA synthesis Kit (BioLINE). RT-PCR reactions were performed using SYBR Green Master Mix (Thermo Scientific) on the Step One Plus Real-Time PCR instrument (Applied Biosystems). The primers for RT-PCR include METLL3 (F 5′-TCA GCA TCG GAA CCA GCA AAG-3′ (SEQ ID NO: 8); R 5′-TCC TGA CTG ACC TTC TTG CTC-3′ (SEQ ID NO: 9)), METLL14 (F 5′-GTT GGA ACA TGG ATA GCC GC-3′ (SEQ ID NO: 10); R 5′-CAA TGC TGT CGG CAC TTT CA-3′ (SEQ ID NO: 11)), CD44 (F 5′-TGA GCA TCG GAT TTG AGA CC-3′ (SEQ ID NO: 12); R 5′-TGT CAT ACT GGG AGG TGT TGG-3′ (SEQ ID NO: 13)), ADAM19 (F 5′-CCT GGA TGG ACA AGA GGA AG-3′ (SEQ ID NO: 14); R 5′-CTC AGC TTT GAG TGG ATG CT-3′ (SEQ ID NO: 15)), EPAH3 (F 5′-GGG CTG GAT CTC TTA TCC ATC-3′ (SEQ ID NO: 16); R 5′-GGA CCC AGT TTG TTC TCA GC -3′ (SEQ ID NO: 17)), KLF4 (F 5′-AAG AGT TCC CAT CTC AAG GC-3′ (SEQ ID NO: 18); R 5′-CCG TGT GTT TAC GGT AGT GC-3′ (SEQ ID NO: 19)), and ACTIN (F 5′-CCG CAA AGA CCT GTA CGC CAA C-3′ (SEQ ID NO: 20); R 5′-CCA GGG CAG TGA TCT CCT TCT G-3′ (SEQ ID NO: 21)). ACTIN was included as the reference gene for normalization. The ΔΔCt method was used for quantification analysis.
Cell growth assay: GSCs were transduced with lentivirus expressing METTL3 or METTL14 shRNA or METTL3 cDNA. Three days later, the transduced cells were seeded at 5×104 cells per well in 24-well plates and cultured for 7 days. Cell number was counted using a hemocytometer.
Sphere formation assay: The sphere formation assay was performed as previously described (Cui et al., 2016). Briefly, three days after viral transduction, the transduced cells were seeded at 1 cell per well in 96-well plates (for those associated with the limiting dilution assay) or 100 cells per well in 48-well plates and cultured for 2 weeks. The sphere number was counted under microscope. The sphere formation rate was defined as the percentage of sphere-forming cells out of the number of starting cells.
Limiting dilution assay: GSCs were transduced with relevant shRNA or METTL3-expressing lentivirus. The transduced GSCs were seeded at 1, 5, 10, 20, 50 and 100 cells per well into 96-well plates. The number of neurospheres in each well was counted two weeks after seeding cells. Extreme limiting dilution analysis was performed using software available at http://bioinf.wehi.edu.au/software/elda.
Treatment of GSCs with the FTO inhibitor MA2: GSCs were seeded at 5×104 cells per well in 48-well plates and cultured overnight. These cells were treated with MA2, a chemical inhibitor of FTO (Huang et al., 2015) at 20, 40, 60, 80 μM or vehicle control and cultured for 48 h. Cell number was counted using a hemocytometer. To determine the effect of MA2 on the level of m6A RNA modification, GSCs were treated with 50 μM MA2 for 48 h. mRNAs were prepared and subjected to m6A dot blot assay. To test the effect of MA2 in limiting dilution assay, GSCs were treated at 40 pM or vehicle control for two weeks.
Animals: All animal-related work was performed under the IACUC protocol 05050 approved by the City of Hope Institutional Animal Care and Use Committee. The 6-8-week-old male and female NSG mice (from the Jackson Laboratory) were used at age- and gender-matched manner. The sample size was determined based on using t-test for two-group independent samples to reach power of 0.8 and the significance level of 0.05. p<0.05 was considered statistically significant.
Viral transduction followed by transplantation: PBT707, PBT003 or PBT726 cells expressing luciferase gene were transduced with lentivirus expressing control shRNA, METTL3 or METTL14 shRNA. One week after virus transduction, cells were transplanted into the frontal lobes of brains of NSG mice by stereotaxic intracranial injection. Briefly, 2×105 dissociated cells in 2 μl PBS were injected into the following site (AP +0.6 mm, ML +1.6 mm and DV −2.6 mm) with a rate of 1 μl min−1. Tumor growth was monitored by bioluminescence xenogen imaging every other week for six to ten weeks. The bioluminescence intensity was quantified. When monitoring tumor growth, investigators were blind to the group allocation during the bioluminescence xenogen imaging and aware of group allocation when assessing the outcome. The survival of mice after cell transplantation was recorded and analyzed.
Introcranial delivery of the FTO inhibitor MA2: PBT003 cells (2×105) transduced with luciferase expressing lentivirus were intracranially transplanted into the frontal lobe of NSG mice at the same coordinates as described above. One week after transplantation, tumors were detected by bioluminescence imaging and mice were treated with MA2 (5 μl of 600 μM MA2 in 1% DMSO in PBS per mouse) or vehicle control by intratumoral injection once a week for four weeks. Tumor growth was monitored by bioluminescence imaging every week for six weeks. The bioluminescence intensity was quantified.
m6A-seq and data analysis: PBT003 cells were transduced with lentivirus expressing control shRNA or relevant shRNA. Seven days after transduction, total RNAs were extracted using Trizol reagent (Ambion). mRNA was further purified using Dynabeads® mRNA purification kit (Ambion, Catalog # 61006). Fragmented RNA was subjected to m6A-immunoprecipitation (m6A IP) using anti-m6A rabbit polyclonal antibody (Synaptic Systems; Catalog # 202003) followed by RNA-sequencing.
Purified mRNA samples from PBT003 cells were used for m6A-seq. RNA fragmentation was performed by sonication at 10 ng μl−1 in 100 μl RNase-free water using Bioruptor Pico (Diagenode) with 30 s on/30 s off cycle for 30 cycles. m6A-immunoprecipitation (m6A IP) and library preparation were performed according to a published protocol (Dominissini et al., 2013). In detail, 2.5 μg affinity purified anti-m6A rabbit polyclonal antibody (Synaptic Systems; Catalog # 202003) and 20 μl Protein A beads (ThermoFisher; Catalog# 10002D) were used for each affinity pull-down. m6A antibody-bound RNAs were eluted with 100 μl elution buffer and recovered by RNA Clean and Concentrator-5 (Zymo), and subjected to RNA library preparation with TruSeq Stranded mRNA Library Prep Kit. Sequencing was carried out on Illumina HiSeq 4000 according to the manufacturer's instructions.
m6A seq samples (inputs and m6A-IPs) were sequenced by Illumina HiSeq 4000 with single end 50-bp read length. The adapters were trimmed by using the FASTX-Toolkit (Pearson et al., 1997). Deep sequencing data were mapped to Human genome version hg38 using Tophat version 2.0 (Trapnell et al., 2009) without any gaps and allowed for at most two mismatches. Input samples were analyzed by Cufflink (v2.2.1) (Trapnell et al., 2010) to generate RPKM (reads per kilobase, per million reads). For input and m6A-IP samples, the longest isoform was used if the gene had multiple isoforms. Aligned reads were extended to 150 bp (average fragments size) and converted from genome-based coordinates to isoform-based coordinates, in order to eliminate the interference from introns in peak calling. The peak calling method was modified from published work (Dominissini et al., 2012). To call m6A peaks, the longest isoform of each gene was scanned using a 100 bp sliding window with 10 bp step. To reduce bias from potential inaccurate gene structure annotation and the arbitrary usage of the longest isoform, windows with read counts less than 1/20 of the top window in both m6A-IP and input sample were excluded. For each gene, the read counts in each window were normalized by the median count of all windows of that gene. A Fisher exact test was used to identify the differential windows between m6A-IP and input samples. The window was called as positive if the FDR <0.01 and log2 (Enrichment Score) ≥1. Overlapping positive windows were merged. The following four numbers were calculated to obtain the enrichment score of each peak (or window): reads count of the m6A-IP samples in the current peak/window (a), median read counts of the m6A-IP sample in all 100 bp windows on the current mRNA (b), reads count of the input sample in the current peak/window (c), and median read counts of the input sample in all 100 bp windows on the current mRNA (d). The enrichment score of each window was calculated as (a×d)/(b×c). The enrichment ratio was calculated as the ratio of enrichment score in two samples. For motif analysis, HOMER (Heinz et al., 2010) was used to search motifs in each set of m6A peaks. The longest isoform of all genes was used as background. For m6A peak distribution analysis, the length of the 5′ UTR, CDS, and 3′ UTR of each gene was normalized into 50 bins, and the normalized peak density in each bin was calculated as the percentage of gene that has m6A peak in that bin. The gene ontology analysis was performed using the DAVID database with biological process classified under default settings.
The accession number for the RNA-seq data presented in this paper is: GSE94808.
Western blot analysis: Twenty μg proteins from the whole cell lysates were used for Western blot analysis. Rabbit anti-METTL3 antibody (1:1000; Proteintech; Catalog # 15073-1-AP), rabbit anti-METTL14 antibody (1:500; Sigma; Catalog# HPA038002), and rabbit anti-GAPDH antibody (1:1000; Santa Cruz Biotechnology; Catalog # sc-25778) were used.
Statistics: Statistical significance was analyzed using the unpaired one-tailed Student's t-test. Values were presented as *p<0.05, **p<0.01, ***p<0.001. Error bars are s.d. of the mean if not stated otherwise. Log-rank test was used for animal survival analysis.
Primary GSCs were isolated from tumor tissues of newly diagnosed WHO grade IV glioblastoma patients and cultured as 3D tumorspheres in a culture condition optimized for GSC enrichment (Brown et al., 2009). Five GSC lines that represent different glioblastoma subtypes were included in this study. Among these GSC lines, PBT003 and PBT726 are classical (C), PBT707 and PBT111 are proneural (P), and PBT017 is mesenchymal (M) (Cui et al., 2016). These GSCs expressed neural stem cell markers, exhibited multipotency, having the ability to give rise to both neurons and astrocytes. Moreover, they could form brain tumors with typical glioblastoma features in transplanted mouse brains as we described previously (Cui et al., 2016). A summary of these cell lines is included in the table in
To determine if m6A modification plays a role in GSC self-renewal and tumorigenesis, METTL3, the catalytic subunit of m6A methyltransferase complex (Bokar et al., 1997; Batista et al., 2014; Liu et al., 2014; Wang et al., 2014; Geula et al., 2015), was knocked down using two distinct shRNAs in the five lines of GSCs, PBT003, PBT707, PBT017, PBT726 and PBT111. Knockdown of METTL3 expression by both shRNAs was confirmed by RT-PCR (
METTL14 is another component of the methyltransferase complex that is critical for m6A methylation (Liu et al., 2014; Ping et al., 2014; Schwartz et al., 2014; Wang et al., 2014). Like METTL3 knockdown, METTL14 knockdown has also been shown to reduce mRNA m6A level (Liu et al., 2014; Schwartz et al., 2014; Wang et al., 2014). To further determine the role of mRNA m6A methylation in GSCs, mRNA m6A level was modified by knocking down METTL14 using two distinct METTL14 shRNAs in GSCs, including PBT003, PBT707, PBT111 and PBT726. knockdown of METTL14 was confirmed by RT-PCR (
In addition to decreasing m6A level by knockdown of METTL3 or METTL14, how increased m6A level affects the growth and self-renewal of GSCs was investigated by overexpressing METTL3. Multiple GSC lines, including PBT003, PBT707, PBT017, PBT726 and PBT111, were transduced with lentivirus expressing control vector or METTL3. mRNAs were isolated from control or METTL3-overexpressing cells, and RT-PCR analysis confirmed the overexpression of METTL3 in GSCs transduced with METTL3-expressing lentivirus (
The dramatic effect of METTL3 or METTL14 KD on GSC growth and self-renewal in vitro led to the test whether knockdown of METTL3 or METTL14 affects the ability of GSCs to form tumors in vivo. The luciferase-expressing PBT707 cells were transduced with lentivirus expressing a control shRNA, a METTL3 shRNA, or a METTL14 shRNA. The transduced cells were orthotopically transplanted into the frontal lobe of NSG mouse brains (
Consistent with the aggressive tumor progression, mice grafted with PBT707 cells with knockdown of METTL3 or METTL14 alone, or knockdown of both METTL3 and METTL14 had considerably worse survival outcome compared to mice grafted with control GSCs (
Similar to what was observed for the PBT707 cell line, when the luciferase-expressing PBT003 cells were transduced with METTL3 shRNA then transplanted into the brains of NSG mice (
In addition to knockdown of METTL3, PBT003 cells were also transduced with lentivirus expressing a METTL14 shRNA or the combination of METTL3 and METTL14 shRNAs. The transduced cells were transplanted into the brains of NSG mice and tumor progression was monitored by xenogen imaging (
Likewise, when PBT726 cells with knockdown of METTL3 or METTL14 were transplanted into the brains of NSG mice, a substantial increase in tumor growth was observed, compared to that in mice transplanted with control cells (
To evaluate the efficacy of modifying m6A level on GSC tumorigenesis in a more clinically relevant system, luciferase reporter-bearing PBT003 cells were transplanted into brains of NSG mice to establish tumors and the mice were treated with an FTO inhibitor that has been shown to modulate mRNA m6A level (Huang et al., 2015). FTO was identified as the first RNA demethylase that oxidatively demethylates m6A in mRNAs (Jia et al., 2011). MA2, the ethyl ester form of meclofenamic acid (MA), an FDA approved non-steroidal anti-inflammatory drug, was recently identified as a selective inhibitor of FTO that increases m6A level in mRNA of human cells (Huang et al., 2015). Indeed, a substantial increase in mRNA m6A level was detected in GSCs treated with 50 μM MA2, as shown by m6A mRNA dot blot analysis (
Next, the effect of MA2 treatment on GSC growth and self-renewal was tested in vitro. A dramatic growth inhibitory effect of MA2 was detected in PBT003 cells at 60 μM and 80 μM doses (
To test the effect of the FTO inhibitor on GSC-initiated tumorigenesis, PBT003-grafted mice were treated with the selective FTO inhibitor MA2 intratumorally once a week for four weeks (
To investigate the mechanism underlying how m6A modification regulates GSC tumorigenesis, RNA-seq was performed to detect gene expression changes in PBT003 cells with knockdown of METTL3 or METTL14. The expression of more than 2,600 transcripts was changed in PBT003 cells with METTL3 or METTL14 knockdown compared to control cells. Among the genes with altered expression, a number of oncogenes, such as ADAM19, EPHA3, and KLF4, were up-regulated and a list of tumor suppressors, such as CDKN2A, BRCA2, and TP53I11, was down-regulated in GSCs with knockdown of METTL3 or METTL14 (
The up-regulated expression of oncogenes, such as ADAM19, EPHA3, and KLF4, in METTL3 or METTL14 knockdown GSCs was confirmed by RT-PCR. In contrast, overexpression of METTL3 or treatment with the FTO inhibitor MA2 led to decreased expression of these genes (
To investigate the m6A modifications in GSC transcriptome, m6A-seq analysis was performed as described (Dominissini et al., 2013). The m6A consensus motif GGAC was identified in PBT003 cells (
Among the genes, the mRNA of which is modified by m6A methylation, a list of them plays critical roles in cell growth and tumorigenesis. For example, the mRNA of ADAM19, a metalloproteinase disintegrin gene that exhibits elevated expression in glioblastoma cells and promotes glioblastoma cell growth and invasiveness (Wildeboer et al., 2006; Mochizuki and Okada, 2007), is m6A methylated. The mRNA expression of ADAM19 is highly elevated in METTL14 KD GSCs, as revealed by increased mRNA reads in METTL14 KD GSCs (shM14-1 input), compared to control GSCs (shC input) (
To study whether METTL3 and METTL14 are associated with the outcome of glioma patients, the expressions of METTL3 and METTL14 in the R2 French database were investigated. It was found that the upregulated expression of METTL3 and METTL14 predicts better survival in glioma patients (
Whether knocking down TLX in vivo could suppress the progression of human GSC-initiated tumors was investigated in a xenograft model. PBT003 cells were transduced with luciferase-expressing lentivirus, which allowed monitoring tumor growth in vivo by bioluminescence imaging. The resultant PBT003 cells were orthotopically transplanted into the frontal lobe of NSG mouse brains to establish tumors. One week after, mice were treated with scrambled control RNA or TLX shRNA-expressing lentivirus by intratumoral injection (
Moreover, PBT003-grafted mice treated with TLX shRNA-expressing virus had much better survival outcome compared to mice treated with scrambled control RNA (
When mice in control group died, brain samples were collected for histological analysis. H&E staining revealed the development of big tumor mass and aggressive tumor invasion across the hemisphere in brains of control mice, whereas in brains of TLX shRNA-treated mice collected at the same time, no or much smaller tumor was detected (
To study whether TLX regulates m6A RNA modification, the level of m6A in TLX wild type mouse brain cells was measured by m6A mRNA dot blot, and compared to that in TLX knockout mouse brain cells. Dramatically elevated m6A level was detected in cells from TLX knockout mouse brain, compared to cells from wild type mouse brain (
To study whether METTL3 works downstream of TLX to regulate the growth and self-renewal of GSCs, an inducible system to double knock down TLX and METTL3 was established. PBT003, PBT707, PBT726, and PBT111 cells were transduced with lentivirus that expresses doxycycline (dox)-inducible TLX shRNA alone or transduced with lentivirus that expresses dox-inducible TLX shRNA together with lentivirus that expresses dox-inducible METTL3 shRNA. Next whether inducible METTL3 knockdown could rescue the inhibitory effect of inducible TLX knockdown on GSC growth and self-renewal was tested. After dox induction, the growth of PBT003, PBT707, PBT726, and PBT111 cells expressing inducible TLX shRNA was reduced when compared to non-induced cells (
As stated above, the foregoing are merely intended to illustrate the various embodiments of the present invention. As such, the specific modifications discussed above are not to be construed as limitations on the scope of the invention. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the scope of the invention, and it is understood that such equivalent embodiments are to be included herein. All references cited herein are incorporated by reference as if fully set forth herein.
The present invention claims the benefit of U.S. Provisional Patent Application No. 62/470,681, entitled “m6A mRNA Modification in Cancer Treatment,” filed Mar. 13, 2017, the content of which is incorporated herein by reference in its entirety.
The present invention was made with government support under Grant Nos. RB4-06277 and TRAN1-08525, awarded by California Institute for Regenerative Medicine. The Government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US18/22231 | 3/13/2018 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62470681 | Mar 2017 | US |
